Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...
The purine/purinergic system has emerged as a fundamental regulator of cellular communication, influencing various physiological processes such as metabolism, energy balance, and signal transduction.